Skip to main content
. 2023 Feb 26;24(5):4568. doi: 10.3390/ijms24054568

Figure 2.

Figure 2

Gut microbial composition in psoriatic patients during the 24 weeks of treatment with IL-23 (guselkumab) or IL-17 (secukinumab and ixekizumab) inhibitors. (A) The distribution of α-diversity (Inverse Simpson’s index) and β-diversity (UniFrac distance) of gut microbiota at weeks 0, 4, 12, and 24 in patients treated with IL-23 or IL-17 inhibitors. (B) The distribution of α-diversity (Inverse Simpson’s index) and β-diversity (Bray–Curtis distance) at weeks 0 and 24 between responders (R) and non-responders (NR) of the two groups. * p < 0.05.